longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response.. 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

esponses	-)													
1. Name and Address of Reporting Person * LANDRY DONALD W			Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306				3. Date of Earliest Transaction (Month/Day/Year) 06/20/2017						Officer (give	e title below)	Othe	r (specify below)	
(Street)										6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
, NY 10	(State)	(Zip)			Tah	le I .	- Non-Derivat	ive Securities	Acquired	Disnosed	of or Rene	eficially Own	ed	
Title of Security nstr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed 3. Tra Execution Date, if Code any (Month/Day/Year)		. Tra ode instr.	nsaction 4. S (A) 8) (Ins	ecurities Acqu or Disposed o tr. 3, 4 and 5)	uired 5. Amount of 3. Owned Follow Transaction(s)		Securities Beneficially ving Reported)		Ownership of orm: Direct (D) r Indirect	eneficial wnership		
ort on a s	eparate line for eac	Table II - l	Derivativ	ve S	ecurities	Acq	Persons containe form disp	who respond in this forrolays a curre ed of, or Bene	n are not ently valid ficially Ow	required OMB co	to respon	d unless th		74 (9-02)
Derivative Conversion Date Execution Date Conversion (Month/Day/Year)		3A. Deemed Execution Date, if any	4. Transaction Code		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
4.18	06/20/2017		A		ì	. ,	06/20/2018	06/20/2027	Commor	20,000	\$ 0 (1)	20,000	D	
F A Si ii	PHARMADISO , NY 10 ity ort on a s version xercise e of ivative urity	PHARMACEUTICALS MADISON AVE., STE 3 (Street) NY 10022 (State) ort on a separate line for each each each each each each each each	PHARMACEUTICALS HOLDING MADISON AVE., STE 306 (Street) NY 10022 (State) 2. Transaction Date (Month/Day/Year) Table II - (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	PHARMACEUTICALS HOLDING (Street) (Street) (State) (Zip) (State) (Zip) (Month/Day/Year) (A) Tonix P (Middle) (06/20/2 (State) (Zip) (Zip) (Month/Day/Year) (Month/Day/Year) (A) Table II - Derivative (e.g., put Execution Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Code Code	Tonix Phar (First) (Middle) PHARMACEUTICALS HOLDING (ADISON AVE., STE 306 (Street) 4. If Amendre (State) (Zip) (State) 2. Transaction Date (Month/Day/Year) ort on a separate line for each class of securities beneficially Table II - Derivative Sector, puts, car (e.g., puts, car (Month/Day/Year) 3. Transaction Date Execution Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) A. Deemed Execution Date (Instr. 8)	DNALD W (First) (Middle) PHARMACEUTICALS HOLDING MADISON AVE., STE 306 (Street) (Street) (State) (Zip) Tab (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, warreversion Date (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, warreversion Date (Month/Day/Year) (Month/Day/Year) A. If Amendment, Date Execution Date, if Clark (any (Month/Day/Year)) Table II - Derivative Securities (e.g., puts, calls, warreversion of Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) A. Deemed Execution Date, if Clark (any (Month/Day/Year)) (Month/Day/Year) (Month/Day/Year) A. Deemed Execution Date, if Clark (any (Month/Day/Year)) (Instr. 8) Code V (A) Code V (A)	DNALD W (First) (PHARMACEUTICALS HOLDING (Street) (State) (State) (Zip) (State) (Zip) (And Disconting the part of	Tonix Pharmaceuticals Holding Cores (First) (Middle) (Mid	Tonix Pharmaceuticals Holding Corp. [TNXP] (First) (Middle) PHARMACEUTICALS HOLDING MADISON AVE., STE 306 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Date of Earliest Transaction (Month/Day/Year) (A) or Disposed of (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) (A) or Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security or indirectly. (Month/Day/Year) 3. Transaction (A) or Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security or indirectly. (Month/Day/Year) 3. Transaction (A) or Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security or indirectly. (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 4. Securities Acquired, (A) or Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security or indirectly. (Month/Day/Year) 5. Number (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 6. Date Exercisable Date (Month/Day/Year) 6. Date Exercisable Date Exercisable Date (Month/Day/Year) 6. Date Exercisable Date Exercisable Date (Month/Day/Year) 6. Date Exercisable Date Exercisable Date Exercisable Date (Month/Day/Year) 6. Date Exercisable Date Exercisable Date Exercisable Date (Month/Day/Year) 6. Date Exercisable Date Exercisable Date (Month/Day/Year) 6. Date Exercisable Date Exercisable Date Exercisable Date Date Date Date Date Exercisable Date Date Date Date Date Date Date Dat	Tonix Pharmaceuticals Holding Corp. [TNXP] X X X X X X X X X	Tonix Pharmaceuticals Holding Corp. [TNXP] (First) (Middle) (PHARMACEUTICALS HOLDING (Month/Day/Year) (Mont	Tonix Pharmaceuticals Holding Corp. [TNXP] (First) (Andalle)	Tonix Pharmaceuticals Holding Corp. [TNXP] PHARMACEUTICALS HOLDING (Street) (State) (State) (State) (State) (State) (State) (State) (State) (A) or Date (Month/Day/Year) (Month	Tonix Pharmaceuticals Holding Corp. [TNXP] PHARMACEUTICALS HOLDING (Sires) 4. If Amendment, Date Original Filed(Month/Day/Year) (Sizes) (Sizes) (Zap) Table I - Non-Derivative Securities Acquired (Month/Day/Year) Date (Month/Day/Year) (Month/Day/Year) Date (Month/Day/Year) (Month/Day/Year) PHARMACEUTICALS HOLDING (Sizes) (Sizes) (Zap) Table I - Non-Derivative Securities Acquired (Month/Day/Year) Date (Month/Day/Year) (Month/Day/Year) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (I) (I) (Instr. 4) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3) Table II - Derivative Securities Date (Month/Day/Year) Securities Date (Month/Day/Year) Date (Month/Day/Year) Date (Month/Day/Year) A Deeped (Instr. 4) Date Securities Date (Month/Day/Year) Date (Month/Day/Year) Date Securities Securities Date (Instr. 3) Date (Month/Day/Year) Date Securities Date (Instr. 4) Date Securities Date (Instr. 5) Date Securities Date (Instr. 4) Date Securities Date (Instr. 4) Date Securities Date (Instr. 5) Date Date Securities Date (Instr. 4) Date Securities Date (Instr. 4) Date Date Securities Date (Instr. 5) Date Securities Date (Instr. 4) Date Date Securities Date (Instr. 4) Date Date Securities Date (Instr. 5) Date Securities Date (Instr. 4) Date Date Securities Date (Instr. 5) Date Securities Date (Instr. 4) Date Date Securities Date (Instr. 4) Date Date Securities Date (Instr. 4) Date Date Date Securities Date (Instr. 5) Date Date Date Date Date (Instr. 4) Date Date Date Date Date Date Date Date

Donation Commun Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
LANDRY DONALD W C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., STE 306 NEW YORK, NY 10022	X					

Signatures

/s/Jessica Morris, Attorney-in-Fact	06/21/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see} \ Instruction 6 \ for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.